HC Wainwright Weighs in on Pelthos Therapeutics Q3 Earnings

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) – Analysts at HC Wainwright issued their Q3 2026 earnings estimates for Pelthos Therapeutics in a report issued on Friday, March 6th. HC Wainwright analyst B. Folkes expects that the company will earn ($1.21) per share for the quarter. HC Wainwright also issued estimates for Pelthos Therapeutics’ Q4 2026 earnings at ($1.33) EPS and FY2030 earnings at $3.91 EPS.

Other equities analysts have also recently issued reports about the company. Roth Mkm lowered their price target on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Oppenheimer upped their price objective on Pelthos Therapeutics from $57.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, January 26th. Piper Sandler assumed coverage on Pelthos Therapeutics in a report on Friday, February 27th. They issued an “overweight” rating and a $48.00 target price on the stock. Finally, Zacks Research cut Pelthos Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, January 30th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $54.33.

Pelthos Therapeutics Stock Up 3.2%

NYSEAMERICAN:PTHS opened at $23.12 on Monday. The company has a market capitalization of $74.91 million, a price-to-earnings ratio of -1.35 and a beta of 3.86. Pelthos Therapeutics has a 12 month low of $9.00 and a 12 month high of $54.29.

Institutional Investors Weigh In On Pelthos Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of PTHS. Persistent Asset Partners Ltd grew its position in shares of Pelthos Therapeutics by 150.0% during the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock worth $186,000 after purchasing an additional 3,604 shares in the last quarter. Millennium Management LLC purchased a new position in Pelthos Therapeutics in the 4th quarter worth approximately $343,000. Geode Capital Management LLC boosted its stake in Pelthos Therapeutics by 31.9% in the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after purchasing an additional 3,295 shares during the period. Knott David M Jr grew its holdings in Pelthos Therapeutics by 215.5% during the 4th quarter. Knott David M Jr now owns 19,281 shares of the company’s stock valued at $598,000 after buying an additional 13,169 shares in the last quarter. Finally, Diadema Partners LP grew its holdings in Pelthos Therapeutics by 138.1% during the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after buying an additional 14,502 shares in the last quarter. 77.96% of the stock is owned by institutional investors.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).